Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations

被引:44
作者
Li, Qinglong [1 ]
Yang, Zhulin [1 ]
机构
[1] Cent S Univ, Xiangya Hosp 2, Res Lab Hepatobiliary Dis, Changsha 410011, Hunan, Peoples R China
关键词
GROWTH-FACTOR RECEPTOR; AKT-SIGNALING PATHWAY; BILIARY-TRACT CANCER; HEPATOCELLULAR-CARCINOMA; CHOLANGIOCARCINOMA; ACTIVATION; CHOLANGLOCARCINOMA; PROGNOSIS; ERK1/2; CELLS;
D O I
10.1186/1756-9966-28-65
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: An increasing number of studies have shown that ERK and PI3-K/AKT signaling pathways are involved in various human cancers including hepatocellular carcinoma and cholangiocarcinoma. However, few studies have examined gallbladder cancer specimens, and little is known about the clinical and pathological significance of ERK1/2 and PI3-K/AKT signaling changes in gallbladder adenocarcinoma. In this study, we examined phospho-ERK1/2 (p-ERK1/2) and PI3K expression and analyzed its clinicopathological impact in gallbladder adenocarcinoma. Methods: Immunohistochemistry was used to detect and compare the frequency of p-ERK1/2 and PI3-K expression in gallbladder adenocarcinoma, peri-tumor tissues, adenomatous polyps, and chronic cholecystitis specimens. Results: The positive staining for p-EKR1/2 and PI3-K were 63/108 (58.3%) and 55/108 (50.9%) in gallbladder adenocarcinoma; 14/46 (30.4%) and 5/46 (10.1%) in peri-tumor tissues; 3/15 (20%) and 3/15 (20%) in adenomatous polyps; and 4/35 (11.4%) and 3/35 (8.6%) in chronic cholecystitis. The positive rate of p-ERK1/2 or PI3-K in gallbladder adenocarcinoma was significantly higher than that in peri-tumor tissue (both, P < 0.01), adenomatous polyps (p-ERK1/2, P < 0.01; PI3-K, P < 0.05), and chronic cholecystitis (both, P < 0.01). The positive staining for p-ERK1/2 or PI3-K was significantly lower in well/highly-differentiated adenocancinomas with maximal diameter >= 2.0 cm, no metastasis to lymph node, and no infiltration of regional tissues or organs compared to poorly-differentiated adenocarcinomas which are characterized by a maximal diameter = 2.0 cm, with metastasis to lymph node and infiltration of regional tissues or organs (P < 0.05 or P < 0.01). Moreover, the frequency of p-ERK1/2 expression in gallbladder adenocarcinomas without gallstone was significantly lower than those with gallstones. Increased expression of p-ERK1/2 (P < 0.05) and PI3K (P = 0.062) was associated with decreased overall survival. Multivariate Cox regression analysis showed that increased p-ERK1/2 expression was an independent prognostic predictor in gallbladder carcinoma (P = 0.028). Conclusion: Increased expression of p-ERK1/2 and PI3K might contribute to gallbladder carcinogenesis. p-ERK1/2 over-expression is correlated with decreased survival and therefore may serve as an important biological marker in development of gallbladder adenocarcinoma.
引用
收藏
页数:8
相关论文
共 26 条
[1]  
CARRIAGA MT, 1995, CANCER-AM CANCER SOC, V75, P171, DOI 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO
[2]  
2-2
[3]   Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer [J].
Hori, Hiroshige ;
Ajiki, Tetsuo ;
Mita, Yoshiyasu ;
Horiuchi, Hideki ;
Hirata, Kenro ;
Matsumoto, Taku ;
Morimoto, Haruki ;
Fujita, Tsunenori ;
Ku, Yonson ;
Kuroda, Yoshikazu .
JOURNAL OF GASTROENTEROLOGY, 2007, 42 (07) :567-572
[4]   Gallstones and the risk of biliary tract cancer: a population-based study in China [J].
Hsing, A. W. ;
Gao, Y-T ;
Han, T-Q ;
Rashid, A. ;
Sakoda, L. C. ;
Wang, B-S ;
Shen, M-C ;
Zhang, B-H ;
Niwa, S. ;
Chen, J. ;
Fraumeni, J. F., Jr. .
BRITISH JOURNAL OF CANCER, 2007, 97 (11) :1577-1582
[5]   Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis [J].
Huynh, H ;
Nguyen, TTT ;
Chow, KHP ;
Tan, PH ;
Soo, KC ;
Tran, E .
BMC GASTROENTEROLOGY, 2003, 3 (1)
[6]   ERBB receptors and cancer: The complexity of targeted inhibitors [J].
Hynes, NE ;
Lane, HA .
NATURE REVIEWS CANCER, 2005, 5 (05) :341-354
[7]   Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholanglocarcinoma cells [J].
Isomoto, H ;
Kobayashi, S ;
Werneburg, NW ;
Bronk, SF ;
Guicciardi, ME ;
Frank, DA ;
Gores, GJ .
HEPATOLOGY, 2005, 42 (06) :1329-1338
[8]   Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma [J].
Ito, Y ;
Takeda, T ;
Sasaki, Y ;
Sakon, M ;
Yamada, T ;
Ishiguro, S ;
Imaoka, S ;
Tsujimoto, M ;
Higashiyama, S ;
Monden, M ;
Matsuura, N .
PATHOLOGY RESEARCH AND PRACTICE, 2001, 197 (02) :95-100
[9]   Akt expression may predict favorable prognosis in cholangiocarcinoma [J].
Javle, Milind M. ;
Yu, Jihnhee ;
Khoury, Thaer ;
Chadha, Krishdeep C. ;
Iyer, Renuka V. ;
Foster, Jason ;
Kuvshinoff, Boris W. ;
Gibbs, John F. ;
Geradts, Joseph ;
D Black, Jennifer ;
Brattain, Michael G. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (11) :1744-1751
[10]   Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma [J].
Jinawath, Artit ;
Akiyama, Yoshimitsu ;
Yuasa, Yasuhito ;
Pairojkul, Chawalit .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (12) :805-810